|Articles|June 16, 2020
Pratia and KFGN Join Forces
Advertisement
Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Operational Strategies That Strengthened the NIMBLE Trial DesignSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
2
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
3
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
4
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
